SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-22-084430
Filing Date
2022-08-01
Accepted
2022-08-01 07:00:12
Documents
2
Group Members
BEN SHAPIROLYNWOOD OPPORTUNITIES MASTER FUND

Document Format Files

Seq Description Document Type Size
1 SC 13G tm2222010d1_sc13g.htm SC 13G 75788
2 EXHIBIT 1 tm2222010d1_ex-1.htm EX-99.1 2987
  Complete submission text file 0001104659-22-084430.txt   80531
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Subject) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: SC 13G | Act: 34 | File No.: 005-92289 | Film No.: 221122704
SIC: 2834 Pharmaceutical Preparations

Mailing Address 200 BAY STREET ROYAL BANK PLAZA SOUTH TOWER, #1304 TORONTO A6 M5J2J1
Business Address 200 BAY STREET ROYAL BANK PLAZA SOUTH TOWER, #1304 TORONTO A6 M5J2J1 416-921-4511
Lynwood Capital Management Inc. (Filed by) CIK: 0001846412 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: SC 13G